A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats

[1]  U. Wisløff,et al.  Endoplasmic reticulum stress impairs cardiomyocyte contractility through JNK-dependent upregulation of BNIP3. , 2018, International journal of cardiology.

[2]  R. Vasan,et al.  Ceramide Remodeling and Risk of Cardiovascular Events and Mortality , 2018, Journal of the American Heart Association.

[3]  Jihui Chen,et al.  Mitochondrial Fission Is Required for Angiotensin II-Induced Cardiomyocyte Apoptosis Mediated by a Sirt1-p53 Signaling Pathway , 2018, Front. Pharmacol..

[4]  R. Gottlieb,et al.  Exercise reestablishes autophagic flux and mitochondrial quality control in heart failure , 2017, Autophagy.

[5]  D. Mochly‐Rosen,et al.  Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics. , 2016, Angewandte Chemie.

[6]  G. Dorn,et al.  Correcting mitochondrial fusion by manipulating mitofusin conformations , 2016, Nature.

[7]  M. Disatnik,et al.  Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo. , 2016, Journal of the American Chemical Society.

[8]  D. Mochly‐Rosen,et al.  Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Protein-Protein Interaction Inhibitor Reveals a Non-catalytic Role for GAPDH Oligomerization in Cell Death* , 2016, The Journal of Biological Chemistry.

[9]  L. Scorrano,et al.  Extracellular Regulated Kinase Phosphorylates Mitofusin 1 to Control Mitochondrial Morphology and Apoptosis , 2015, Molecular cell.

[10]  L. Wilkins.  Circulation: Clinical Summaries Original Research Put Into Perspective for the Practicing Clinician , 2008, Circulation.

[11]  M. Disatnik,et al.  Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling. , 2014, Cardiovascular research.

[12]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[13]  J. Campos,et al.  Acute Inhibition of Excessive Mitochondrial Fission After Myocardial Infarction Prevents Long‐term Cardiac Dysfunction , 2013, Journal of the American Heart Association.

[14]  D. Mochly‐Rosen,et al.  A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity , 2013, Journal of Cell Science.

[15]  J. Campos,et al.  Exercise Training Restores Cardiac Protein Quality Control in Heart Failure , 2012, PloS one.

[16]  K. Das,et al.  Protein kinase C, an elusive therapeutic target? , 2012, Nature Reviews Drug Discovery.

[17]  T. Veenstra,et al.  Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis. , 2012, Molecules and Cells.

[18]  Julio C. B. Ferreira,et al.  Protein Quality Control Disruption by PKCβII in Heart Failure; Rescue by the Selective PKCβII Inhibitor, βIIV5-3 , 2012, PloS one.

[19]  R. Kloner,et al.  An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. , 2012, Journal of the American College of Cardiology.

[20]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[21]  G. Dorn,et al.  Mitochondrial Fusion is Essential for Organelle Function and Cardiac Homeostasis , 2011, Circulation research.

[22]  D. Bernstein,et al.  Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. , 2011, Journal of molecular and cellular cardiology.

[23]  Julio C. B. Ferreira,et al.  βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. , 2011, Journal of molecular and cellular cardiology.

[24]  Daria Mochly-Rosen,et al.  PKCβII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses , 2011, Journal of cellular and molecular medicine.

[25]  D. Xing,et al.  Mitochondrial oxidative stress causes mitochondrial fragmentation via differential modulation of mitochondrial fission–fusion proteins , 2011, The FEBS journal.

[26]  K. Kolaja,et al.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.

[27]  R. Sobel,et al.  Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo , 2011, Molecular biology of the cell.

[28]  R. Youle,et al.  Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin , 2010, The Journal of cell biology.

[29]  D. Mochly‐Rosen,et al.  Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure. , 2010, Drug discovery today. Disease mechanisms.

[30]  Q. Lu,et al.  Phosphorylation of Cardiac Troponin I at Protein Kinase C Site Threonine 144 Depresses Cooperative Activation of Thin Filaments* , 2010, The Journal of Biological Chemistry.

[31]  E. B. Tahara,et al.  Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. , 2009, Free radical biology & medicine.

[32]  S. Palaniyandi,et al.  Protein kinase C in heart failure: a therapeutic target? , 2008, Cardiovascular research.

[33]  C. Granger,et al.  Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction , 2008, Circulation.

[34]  Cecilia Hidalgo,et al.  Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. , 2008, Cardiovascular research.

[35]  A. Kowaltowski,et al.  Pharmacological and physiological stimuli do not promote Ca(2+)-sensitive K+ channel activity in isolated heart mitochondria. , 2007, Cardiovascular research.

[36]  S. Minucci,et al.  Protein Kinase C ß and Prolyl Isomerase 1 Regulate Mitochondrial Effects of the Life-Span Determinant p66Shc , 2007, Science.

[37]  K. Mihara,et al.  Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity , 2004, Journal of Cell Science.

[38]  P. Yock,et al.  Inhibition of &dgr;-Protein Kinase C Protects Against Reperfusion Injury of the Ischemic Heart In Vivo , 2003, Circulation.

[39]  A. Clerk,et al.  Kinases as therapeutic targets for heart failure , 2003, Nature Reviews Drug Discovery.

[40]  D. Mochly‐Rosen,et al.  Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). , 2001, Chemistry & biology.

[41]  D. Mochly‐Rosen,et al.  Binding Specificity for RACK1 Resides in the V5 Region of βII Protein Kinase C* , 2001, The Journal of Biological Chemistry.

[42]  S. Vanni,et al.  Cardiac Angiotensin II Formation in the Clinical Course of Heart Failure and Its Relationship With Left Ventricular Function , 2001, Circulation research.

[43]  D. Mochly‐Rosen,et al.  Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C. , 2001, The Journal of biological chemistry.

[44]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[45]  D. Mochly‐Rosen,et al.  Peptide modulators of protein–protein interactions in intracellular signaling , 1998, Nature Biotechnology.

[46]  R. Bonow,et al.  Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.

[47]  D. Mochly‐Rosen,et al.  An autoregulatory region in protein kinase C: the pseudoanchoring site. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Caldwell,et al.  Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  X. Huang.  Treatment of urinary retention with acupuncture and moxibustion. , 1991, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[50]  D. Lipman,et al.  Improved tools for biological sequence comparison. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[51]  N. Kruger,et al.  The bradford method for protein quantitation. , 1988, Methods in molecular biology.

[52]  M. Karnovsky.  THE LOCALIZATION OF CHOLINESTERASE ACTIVITY IN RAT CARDIAC MUSCLE BY ELECTRON MICROSCOPY , 1964, The Journal of cell biology.

[53]  T N P JOHNS,et al.  EXPERIMENTAL MYOCARDIAL INFARCTION. I. A. METHOD OF CORONARY OCCLUSION IN SMALL ANIMALS , 1954, Annals of surgery.